SCHEMBL7011395

SCHEMBL7011395

CCOC(=O)CC(=O)N1CCC(C(=O)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.51
ALDH1A1 P00352 6/20 0.49
GAA P10253 3/20 0.49
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
PKM P14618 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8892219 0.86 ALOX15 (0.50) ALOX15ALDH1A1GAAMAPTMEN1
SCHEMBL16653579 0.83 ALOX15 (0.54) ALOX15ALDH1A1GAAMAPTMEN1
SCHEMBL4210140 0.81 GAA (0.71) ALDH1A1GAAMAPTTSHRPKM
SCHEMBL12496081 0.80 ALOX15 (0.53) ALOX15ALDH1A1GAAMAPTMEN1
SCHEMBL16653372 0.79 ALOX15 (0.50) ALOX15ALDH1A1GAAMAPTMEN1
SCHEMBL11191041 0.79 ALOX15 (0.56) ALOX15ALDH1A1GAAMEN1TSHR
SCHEMBL7014898 0.78 MAPT (0.58) ALDH1A1GAAMAPTMEN1TSHR
SCHEMBL11191103 0.78 ALOX15 (0.54) ALOX15ALDH1A1GAAMEN1TSHR
SCHEMBL9527006 0.78 ALOX15 (0.54) ALOX15ALDH1A1GAAMEN1TSHR
SCHEMBL14902196 0.78 LMNA (0.51) ALDH1A1GAAMAPTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224186-B1 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION MILLENNIUM PHARM INC (US) 2003-09-24 EP disclosed
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation MILLENNIUM PHARMACEUTICALS, INC. 2003-03-20 US disclosed
EP-1224186-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2002-07-24 EP disclosed
WO-2001030780-A2 PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION COR THERAPEUTICS, INC. (US) 2001-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055244-A1 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation PF4, PFKP, FGB ALOX15 2563/4885ALDH1A1 2226/4885GAA 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.